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Abstract
Many trace elements, among which metals, are indispensable for proper functioning of a myriad of biochemical
reactions, more particularly as enzyme cofactors. This is particularly true for the vast set of processes involved in
regulation of glucose homeostasis, being it in glucose metabolism itself or in hormonal control, especially insulin.
The role and importance of trace elements such as chromium, zinc, selenium, lithium and vanadium are much less
evident and subjected to chronic debate. This review updates our actual knowledge concerning these five trace
elements. A careful survey of the literature shows that while theoretical postulates from some key roles of these
elements had led to real hopes for therapy of insulin resistance and diabetes, the limited experience based on
available data indicates that beneficial effects and use of most of them are subjected to caution, given the narrow
window between safe and unsafe doses. Clear therapeutic benefit in these pathologies is presently doubtful but
some data indicate that these metals may have a clinical interest in patients presenting deficiencies in individual
metal levels. The same holds true for an association of some trace elements such as chromium or zinc with oral
antidiabetics. However, this area is essentially unexplored in adequate clinical trials, which are worth being
performed.
Introduction
Many trace elements, among which metals, involved as
cofactors in myriads of biochemical-especially-enzymatic
reactions. As such they play cardinal roles in many phy-
siological processes, in particular immunity and metabo-
lism. A good example to illustrate their important
contribution is magnesium: low magnesium levels have
been associated with increased type 2 diabetes [1,2],
whereas controversy exists about the importance of
hypomagnesaemia in prediabetic states [3].
Trace elements have been identified for long time as
potential candidates for improving metabolic disorders
like prediabetes [insulin resistance, obesity, metabolic
syndrome] or diabetes. In parallel with increasing com-
prehension of cellular and biochemical mechanisms
leading to-or aggravating- these metabolic disorders,
identifying the cellular targets and sites of action of
trace elements has reactivated interest in their therapeu-
tic potential. Activation of insulin receptor signalling
(chromium), antioxidant properties (selenium, zinc) or
inhibition of phosphatases (vanadium) thus appeared
promising in view of the key importance of these pro-
cesses in glucose homeostasis and insulin sensitivity.
Indeed insulin receptor/postreceptor signalling defects
are considered to underlie glycemic dysregulation and
insulin resistance, although the precise causal defects
must still be unravelled [4,5]. Prediabetic states, and
even more so frank diabetes, are characterized by
inflammation [cytokines] and oxidative stress, due to
disruption of the equilibrium between production of
free radicals and their scavenging by multiple antioxi-
dant systems [6-8]. Moreover, these mechanisms may be
involved in concert in the pathogenesis of insulin resis-
tance and accompanying pathologies [9].
The present review updates our actual state of knowl-
edge about those five trace elements (chromium, zinc,
selenium, vanadium, lithium)which have a therapeutic
potential in insulin resistance and diabetes, describing
their mechanisms of action and their efficacy in both
animal and human investigations.
Chromium
General aspects
The importance of chromium (Cr) for glucose metabolic
regulation has been seen in clinical states of relatively
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tolerance, fasting hyperglycaemia and eventually lipid
disorders [10,11]. Severe deficiencies are mostly limited
to parenteral nutrition but analysis of diet plans cur-
rently in use in United States reveals a lack of Cr in
many diets, potentially linked to various chronic diseases
[12]. The safe and adequate daily intake of Cr was con-
sidered to be in the range 50-200 mg. However, now
30 mg/d seems a newly admitted value. Cr is found in
relatively high amounts in barley [13]. Cr is poorly
absorbed and only toxic in high doses, depending on the
milieu, the tissues and the valence of the metal: hexava-
lent Cr is highly toxic whereas the in vivo toxicity of tri-
valent Cr is debated [10,14]. After a period of intense
utilization, Cr seems to be less popular nowadays, as
recently reviewed [15]. Studies performed over the last
20 years in both animals and humans have been largely
criticized and whether Cr is indeed an essential element
has been questioned [15,16].
Cr has no effect in healthy individuals and, because
these are not Cr-deficient, there is no need for supple-
mentation. Cr has been administered and tested
in various forms such as Cr-chloride, Cr-nicotinate,
Cr-proprionate, Cr-histidinate or Cr-picolinate, the lat-
ter being by far the best investigated form because of its
solubility in water at neutral pH. However in acidic
milieu it hydrolyzes and it has been shown that only
about 1% of absorbed Cr is found in the bloodstream
[15]. Most of the studies published about biological
effects of Cr have indeed used Cr-picolinate. Recently
new forms aimed at improving Cr bioavailability have
been investigated: a complex of Cr and D-phenylalanine
[17], Cr-dinicocysteinate [18] and a combination of Cr
and biotin [19].
Mechanisms of action
Several mechanistic studies showed improvements in
insulin receptor/postreceptor signalling, leading to
increased glucose transport by enhanced activity of the
hormone-sensitive GLUT-4 transporters. These effects
can be due to the receptor itself, its control mechanisms
or its immediate environment in the cell membrane. Cr-
picolinate was shown to induce various effects: increase
in AMPKinase and p38 MAPkinase activities [20],
increase in receptor phosphorylation [21] and increase
in insulin receptor mRNA (in addition to mRNA for
GLUT-4, glycogen synthase and UCP3) [22]. Increased
synthesis of IGF receptors, able to functionally replace
failing insulin receptors, was also described [23].
Changes in the environment of insulin receptors were
shown as reductions in plasma membrane cholesterol
[24,25], leading to improved cytoskeletal functioning
and enhanced insulin sensitivity. Decreases in TNFa
[26,27], resistin [28], interleukin-6, CRP [27] as well as
increases in vitamin C or adiponectin [29] were all posi-
tive mechanisms to reduce insulin resistance by Cr.
Finally, one should mention that Cr can bind directly
to insulin, in particular to insulin dimers [30], thereby
possibly stabilizing the hormone structure and/or modi-
fying its receptor binding. Interestingly the Cr binding
to insulin receptors occurs o nas e q u e n c eo f3a m i n o a -
cids which are identical to those described for GTF dec-
ades ago (see below).
Biological effects
The appearance of glucose intolerance or even fasting
hyperglycaemia in demonstrated cases of Cr deficiency
have rapidly led to investigations on the potential of Cr
supplementation in insulin resistance and diabetes.
Furthermore, diabetic patients have about 1/3 less Cr in
various biological samples [31-33]. The reasons for this
have recently been discussed [15]. While it was shown
that inorganic Cr was poorly active, Mertz and cowor-
kers identified as early as 1955 a complex found in
brewer’s yeast, liver and kidney which was able to stimu-
late glucose transport in the presence-but not in
absence- of insulin and which contained Cr. They
termed it GTF [glucose tolerance factor]. Its activity
required insulin and was dependent on its Cr content,
ideally 4 ions/molecule, while 8 ions/molecule revealed
toxic [34,35]. GTF (MW about 1500) appeared to be a
mixture of Cr, nicotinic acid and the 3 aminoacids con-
stitutive of glutathione [36]. Replacement of Cr by other
metals did not reproduce GTF biological activity. It
increased insulin efficacy in adipocytes [35,37] at rela-
tively high concentrations but no effects was found in
diabetic patients despite demonstrable increases in Cr
content of various tissues [38]. Presently the GTF story
is highly criticized because of missing informations and
doubtful technical purification procedures [15]. The
GTF story continued with description of a similar struc-
ture termed LMWCr.
As for many therapeutic trials, concern must be raised
as to the concentrations used. Especially in vitro and in
animals studies are usually performed with irrelevant
concentrations of the active compound, leading to so-
called “pharmacological” effects. Accordingly these data
should be viewed with appropriate caution. In vitro
many beneficial effects of Cr salts have been reported
for insulin resistance or diabetes; Cr chloride increased
glucose transport in fat and muscle cells as well as in
cardiomyocytes [17,25,35]. This was partly explained by
higher translocation of Glut-4 transporters [20]. It also
decreased oxidative stress, glycosylation and lipid perox-
idation in erythrocytes and monocytes under hypergly-
caemic conditions [26,39-42].
In animals Cr-picolinate reduced AUC for glucose in
type1 diabetic rats [37]. Insulin resistance improved in
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[44], in Zucker diabetic fatty rats [29], in GK rats
[45,46], in JCR-LA corpulent rats [47] and in db/db
mice [48]. A study in obese Zucker rats failed to report
improvements [49].
In addition to positive effects on glucose and insulin
metabolic profiles, some studies also reported reduction
in triglycerides [37] and stimulation of b-oxidation [50].
In contrast to animal studies, human studies look
much more controversial. This may be due to large dif-
ferences in Cr administration protocols. Positive reports
with Cr exist in type2 diabetics treated with sulfonylur-
eas [51] or in combination with either biotin [52] or
vitamins C and E [53]. Many human studies failed to
see improvements in diabetes, as evidenced by reviews
and meta-analyses [54-56]. It is likely that patient selec-
tion is cardinal [57] and that Cr supplementation is pri-
marily of interest in patients suffering from clearcut Cr
deficiency if the aim is to reduce hyperglycaemia [58] or
as an adjuvant to already-existing treatment with oral
antidiabetics. Changes in blood lipids in humans were
not conclusive.
Based on mechanistic hypotheses (see below) the best
application might be insulin resistance (prediabetes,
metabolic syndrome), although this is also controversial:
reduction in insulin resistance was observed in diabetics
[53,59] but also in obese women suffering polycystic
ovary syndrome [60]. Another study in metabolic syn-
drome found no effect, however [61].
Zinc
General aspects
Zinc (Zn) is an essential micronutrient which has an
important role in the functioning of hundreds of
enzymes [62], in insulin metabolism and acts as an effi-
cient antioxidant [63,64]. Consequently many observa-
tions relate to Zn deficiency, although clinical signs of
deficiency are quite modest. Zn is found mainly in cer-
eals, meat, seafood and dairy products [65]. Although
usual intakes of Zn are harmless, the range between safe
and unsafe is relatively narrow [66]. Because Zn has no
storage form, there is need for a constant supply and Zn
availability to cells is particularly well regulated, albeit
poorly understood [67,68]. Zn absorption can be
reduced by iron or inflammatory bowel diseases. It is
transported across cell membranes via two families of
transporters: ZnT which stimulate Zn efflux and Zip
which stimulate its influx [69]. Over 20 transporters are
identified and most are intracellular [70]. The implica-
tion and regulation of Zn transporters in chronic dis-
eases has been reviewed [71,72]. Concerning metabolic
diseases (insulin resistance, metabolic syndrome, dia-
betes), Zn is considered important mainly because 1) it
plays a major role in the stabilization of insulin
hexamers and the pancreatic storage of the hormone
[73] and 2) it is an efficient antioxidant [74], while oxi-
dative stress is considered to be a main component in
initiation and progression of insulin resistance and dia-
betes [7,75].
Severe Zn deficiency is not frequent but concerns
have nevertheless been raised about Zn levels in diabetic
patients because of increased excretion due to polyuria.
Whereas some studies have reported Zn deficiency in
type 2 diabetes [31,76-78], others failed to find signifi-
cant differences with healthy subjects [79,80]. In type 1
diabetes, Zn deficiency is expected to increase the pan-
creatic damage [81]. A recent report described reduced
levels of Zn in obese, insulin resistant subjects [82].
Lower Zn plasma concentrations were found in type 2
diabetics but they were not related to glycemic status or
diabetes duration or components of the metabolic syn-
drome [83]. Interestingly it was reported that diabetic
have elevated levels of copper [78,80] and it could be
that copper is in fact linked to metabolic syndrome and
diabetes [80,84]. Nevertheless, reduced Zn levels in dia-
betics appear to be related to increased risk for coronary
artery disease [77] and mortality [85].
Mechanisms of action
Several modes of action have been described to explain
the improved action of insulin by Zn. It appears that
Z nc a nh a v ed i r e c ti n s u l i n - l i k ee f f e c t s ,w h i c hm a yb e
due to inhibition of the important glycogen-regulating
enzyme GSK3 [86]. Other mechanisms include stimu-
lation of the postreceptor proteins Akt and PI3-kinase.
Zn can also reduce cytokines such as IL-1b as well as
NFB [87,88]. Zn induces metallothionein synthesis,
whereby Zn may have indirect efficacy [87]. Finally it
has been suggested that the important Zn concentra-
tions for its action are the intracellular -rather than
plasma- levels [89].
Zn is a remarkable antioxidant: it acts at specific sites
where it can compete for iron and copper; it further
binds to SH groups in proteins, protecting them from
oxidation [90]. Because Zn controls metallothionein
expression it is involved in cellular redox regulation
[91,92]. Oxidative stress can be corrected by dietary Zn
as demonstrated by an elevation of hepatic antioxidant
enzymes [93]. In contrast, a recent study showed that in
vitro even micromolar concentrations were cytotoxic
under prevailing H2O2-induced oxidative stress [94].
The latter finding is in line with many observations on
prooxidant potential of antioxidants, according to doses
and present situation [95,96].
Biological effects
Despite the potential interest in Zn in diabetes only some
investigations have been published (reviewed in 62).
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Zn prevented the development of type 1 diabetes induced
by alloxan or streptozotocin [87]. In a study on Zn
restriction during pregnancy in rats, offsprings presented
reduced body weight, increased fat mass and low lean
mass and showed reduced insulin response to glucose
challenge. Zn supplementation corrected the situation
only in females [97]. In db/db mice Zn reduced hypergly-
caemia and hyperinsulinaemia [98]. Administration of Zn
for 3 months reduced proteinuria [99]. Zn restriction
increased oxidative stress and the levels of isoprostanes
[100], in line with antioxidant effects of Zn. Excessive Zn,
on the other hand, increased metabolic syndrome in rats
fed a high fat/sucrose diet [101]; this could be reversed
by copper and magnesium-enriched poultry egg [102].
High Zn slightly reduced the risk for type 2 diabetes
in a prospective study performed in 8300 women and
the effect was limited to the Zn-deficient subgroup
[103]. Another study, however, reported aggravation of
glucose intolerance in Zn-deficient diabetic patients
[104]. In microalbuminuric type 2 diabetic patients Zn
lowered homocysteine levels while increasing vitamin
B12 and folate levels [105]. In obese, non-diabetic sub-
jects insulin sensitivity was improved without changes in
leptin levels [106]. However no preventive effect against
diabetes development could be found in obese women
[107]. Oxidative stress was reduced by Zn in healthy
elderly subjects [108].
Some particular forms of Zn have been tested
recently. Zn-a2-glycoprotein [ZAG] is an adipokine
which stimulates energy expenditure in skeletal muscle
and brown adipose tissue, resulting in reductions in
body weight, glycaemia, triglycerides and NEFAs as
found in ob/ob mice. It increases the pancreatic insulin
content and improves the glucose tolerance test [109].
Its levels are lower in obese human subcutaneous and
visceral adipose tissue and liver, but interestingly does
not appear to be related to insulin resistance [110].
Zn-dithiocarbamate and a complex of Zn with garlic-
originated allixin improved diabetes in KK mice
[111,112].
Selenium
General aspects
Selenium (Se) is relatively well absorbed from diet, bet-
ter so if it is in an organic form [113]. It acts as an anti-
oxidant in the form of selenoproteins which contain
selenocysteins [114]. About 10 different selenoproteins
are described, the best known being glutathione peroxi-
dases, thioredoxin reductases and iodothyronine deiodi-
nases [115]. Selenoproteins are also responsible for the
transport of Se to tissues [116,117]. Severe Se deficiency
is rare, while reduced Se levels are seen in diabetics
together with increased oxidative stress. In offsprings of
diabetic patients Se correlates inversely with CRP and
with insulin resistance if Se levels are below 80 μg/l
[118]. Excess of Se results in excessive oxidative stress
and inflammation as well as diseases like idiopathic sco-
liosis in adolescents [119] or amyotrophic lateral sclero-
sis [120]. Presently a lively debate exists as to the
benefit of supranutritional doses of Se in cancer [121].
Biological effects
In view of the potent antioxidant [122,123] and anti-
inflammatory effects of Se and the prominent role
played by these disorders in insulin resistance and dia-
betes, supplementation with Se in such diseases appears
worthwhile. Interestingly there are only few studies
available.
In vitro Se inhibited hyperglycaemia or hyperinsuli-
naemia-induced expression of adhesion molecules via
reduction in p38MAPkinase [124]. It also reduced
NFB, thereby reducing inflammation, CRP and soluble
L-selectin [125].
In type 1 diabetic rats Na-selenite protected mito-
chondria from oxidative stress [126]. Another study
showed a better effect with Se-methionine than with
Na-selenate [127], confirming other data [128]. In db/db
mice selenate reduced gluconeogenesis and inhibited
phosphotyrosine phosphatases by 50% [129]. This effect
was attributed to formation of selenite from selenate.
In humans lower levels of sialic acid and triglycerides
were reported in young adults having the highest dietary
Se intake [130]. Reduction in complement factor 3 [C3]
where also reported, which may be beneficial consider-
ing the link between C3 and body mass index, skin
thickness and triglycerides [131]. However no positive
effect was found on diabetes prevention and some data
even pointed towards an increased risk [132]. A cross-
sectional study in almost 9000 american adults as well
as another analysis reported a positive link between high
Se levels and diabetes [133,134]. Therefore, as is the
case for use of high Se in cancer [135], caution applies
to utilization of Se supplementation in diabetes, espe-
cially since quite high doses are required to observe
beneficial effects [113,129].
Vanadium
General aspects
Vanadium (Va) has been known for about one century
to possess antidiabetic properties [136]. However only
over the past 2 decades have concrete therapeutic appli-
cations been performed. In humans it is uncertain
whether Va is an essential element and it is poorly
absorbed in its inorganic form. In vivo Va is trans-
formed into vanadyl cations via glutathione and com-
plexes with ferritin and transferrin [137]. Indeed Va is
known to accumulate in some tissues and concerns
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l e s i o n sa sw e l la sl o s so fw e i g h ta n dg a s t r o i n t e s t i n a ld i s -
comfort are well described side-effects of Va, in particu-
lar with inorganic Va, whereas organic Va complexes
appear more safe [137,138]. Recent reports on Va toxicity
show mitochondrial lesions, manifested as swelling and
opening of the membrane transition pore due to oxida-
tive stress [139]. Lung cancer in mice is another recently
described complication with Va pentoxide [140].
Mechanisms of action
Va is usually described as “insulin mimetic”,i nv i e wo fs e v -
eral in vitro experiments looking at insulin receptor signal-
ing. The most evident mechanisms is an inhibition of
phosphotyrosine phosphatases, leading to increased phos-
phorylation of IRS-1, PKB, GSK3 and FOXO1 [141,142].
Inhibition of phosphatases is supposed to result from pro-
duction of peroxyvanadate [137]. Restoration of glucoki-
nase activity was reported in the liver of Va-treated
diabetic rats [143]. An ex vivo study in Va-treated gerbils
suggested that Va was potentiating, rather than mimick-
ing, insulin and that the main action was on GLUT-4 traf-
ficking [144]. This could explain its poor effects in insulin
resistant, normoglycaemic states [145,146].
Biological effects
In animals; many positive reports exist showing benefi-
cial effects of various Va salts in mild or severe diabetes.
F o re x a m p l e ,V as u l p h a t eo rm o r ee l a b o r a t e do r g a n i c
complexes such as bis(maltolato)oxovanadium [BMOV]
have proven efficacy in both type 1 and type 2 models
[144,147]. More recently arylalkylamine derivatives
reduced glycaemia in various models, alone [148] or in
combination (as low doses) with substrates of semicar-
bazide-sensitive aminooxidase SSAO [149].
In humans many trials were performed. However, as
exposed in a review [150], almost all these trials were
short-term and included few patients. Glycaemia-
reducing activity was seen at doses of 100 mg/d or
more [145,151-153]. No efficacy was found, however,
in obese non diabetic subjects [145] or in patients with
impaired glucose tolerance [146]. Improvements in
insulin-sensitivity were claimed to be due to a hepatic
effect rather than to an improvement in peripheral
insulin resistance [154]. Recently the newer derivatives
BEOV and BMOV have entered clinical phase II inves-
tigations [155].
Lithium
General aspects
Lithium (Li) is a complex trace element mainly used in
neurological disorders and more particularly for treating
mood and bipolar disorders. Its clinical management is
difficult and Li is likely toxic [156,157].
Mechanisms of action
The interest in Li is based on its ability to inhibit GSK3
[158,159], a key enzyme regulating tissue glycogen levels
[160,161]. Glycogen metabolism, on the other hand, is a
particularly important component of glucose homeosta-
sis [162]. GSK3 is now also claimed to be involved in
bipolar disorders [163]. Very interestingly the prevalence
of metabolic dysregulation and diabetes is highly aug-
mented in bipolar disorders [164,165]. Transient dia-
betes has been associated with Li withdrawal, pointing
to the potential effect of this trace element [166].
Biological effects
In vitro Li increased both basal and insulin-stimulated
glucose transport, as well as glycogen synthesis in soleus
muscle of insulin resistant, obese Zucker rats [167]. The
effect operated via increasing p38MAPKinase, confirm-
ing previous similar findings [168].
In vivo Li paradoxically increased glycaemia when
administered intravenously to diabetic rats, as shown by
increases in glucagon [169]. Another study showed para-
doxical effects of oral Li in rat liver: while glycogen
synthase was activated and glycogen phosphorylase was
decreased, liver glycogen nevertheless decreased [170].
Altogether these data do not support the use of
lithium in diabetes despite a cellular target (GSK3)
which is potentially of particular interest.
Conclusion
As a whole, this review shows that trace element supple-
mentation as monotherapy is of weak efficacy in dia-
betes and hardly efficacious in prediabetic states. The
global outcome in humans is somewhat frustrating in
view of the logical good expectations from mechanistic
effects of these metals at key steps of glucose and insu-
lin regulatory control [171]. As such, these data nicely
illustrate a classical observation, i.e. that caution should
be given to extrapolations from in vitro or animal data
to real human pathology: the data indeed reveal a clear
discrepancy between both types of studies. There is little
doubt that at least one should 1) better define adequate
oral doses and 2) that patient selection should be much
m o r es e v e r e .F r o me x i s t i n gd a t ai ta p p e a r st h a ti np r e -
diabetic or diabetes, trace elements have no or little
beneficial effect if the patients do not present deficien-
cies. It should be stressed out that for all these metals
organic derivatives yielded much better results than
inorganic forms, likely because of better absorption.
Furthermore they could even induce aggravation of
metabolic disorders, in line with known inversions of
effects of antioxidants at supraphysiological doses. Alter-
natively the positive effects of micronutrient supplemen-
tation is only observed on surrogate parameters such as
blood levels of mediators of inflammation and oxidative
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nying improvement in glycaemic control. Another con-
cern is the relatively narrow range between safe and
unsafe doses for oral treatment of human individuals.
Although surprisingly few data are available, our belief is
that trace elements are of benefit in certain conditions:
individual reports indeed suggest that they are of value in
situations of trace element deficiency and possibly also in
combination with either other trace elements or antioxi-
dants or oral antidiabetics [172,173]. In a model of moder-
ate type 2 diabetes, we found that chronic treatment for 2
weeks using an association of Zn with metformin reduced
fasting glycaemia by 30% over metformin alone, while Zn
alone was without effect (Rapin and Wiernsperger, unpub-
lished data). Finally trace elements may also be of particu-
lar interest in pre/postnatal periods since deficiencies
during pregnancy have negative consequences on several
constitutive and metabolic parameters: in rat offsprings
chromium restriction of mothers during pregnancy
resulted in increased visceral adiposity [174], reduced ske-
letal muscle development and increased basal glucose
uptake [175]. Use of a mineral-restricted diet in female
weanling rats for 12 weeks resulted in increased body fat
and triacylglycerol in offsprings [176].
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